|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Doxazosin#Pharmacology]] |
| {{drugbox
| |
| | IUPAC_name = [4-(4-amino-6,7-dimethoxy- quinazolin-2-yl) piperazin-1-yl]- (2,5-dioxabicyclo[4.4.0] deca-6,8,10-trien-4-yl) methanone
| |
| | image = Doxazosin_svg.png
| |
| | CAS_number = 74191-85-8
| |
| | ATC_prefix = C02
| |
| | ATC_suffix = CA04
| |
| | ATC_supplemental =
| |
| | PubChem = 3157
| |
| | DrugBank = APRD00474
| |
| | C = 23 | H = 25 | N = 5 | O = 5
| |
| | molecular_weight = 451.475 g/mol
| |
| | bioavailability = 65%
| |
| | protein_bound = 98%
| |
| | metabolism = [[Liver|Hepatic]]
| |
| | elimination_half-life = 22 hours
| |
| | elimination =
| |
| | pregnancy_category =
| |
| | legal_status = Rx-only
| |
| | routes_of_administration = oral
| |
| }}
| |
| {{SI}}
| |
| {{CMG}}
| |
| | |
| {{Editor Join}}
| |
| ==[[Doxazosin (patient information)|For patient information, click here]]==
| |
| | |
| '''Doxazosin mesylate''', a [[quinazoline]] compound sold by [[Pfizer]] under the brand name '''Cardura®''', is an [[alpha blocker]] used to treat [[high blood pressure]] and [[benign prostatic hyperplasia]].
| |
| | |
| It is an [[alpha blocker|alpha adrenergic receptor blocker]] which inhibits the binding of [[norepinephrine]] to [[adrenergic receptor|alpha receptors]] in the [[autonomic nervous system]]. The primary effect of this blockage is relaxed vascular [[smooth muscle]] tone ([[vasodilation]]), which decreases [[peripheral vascular resistance]], leading to decreased [[blood pressure]].
| |
| | |
| ==Efficacy==
| |
| In March 2000, the ALLHAT study stopped the arm of its trial looking at alpha blockers because doxazosin (Cardura) was less effective than a simple diuretic. Patients on Cardura had a 25% higher rate of [[cardiovascular disease]] and twice the rate of [[congestive heart failure]] as patients on diuretics<ref>{{cite journal |author=Piller LB, Davis BR, Cutler JA, ''et al'' |title=Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone |journal=Curr Control Trials Cardiovasc Med |volume=3 |issue=1 |pages=10 |year=2002 |month=November |pmid=12459039 |doi=10.1186/1468-6708-3-10 |url=}}</ref>. Pfizer, aware of the results before publication, launched a sophisticated damage control campaign in early 2000, and sales were largely unaffected despite the dangers highlighted by the study<ref>{{cite web |url=http://www.bmj.com/cgi/content/full/326/7381/170/DC1 |title=Marketing: Spin doctors soft pedal data on antihypertensives |publisher=[[BMJ]] |date=2003-01-18|format= |work= |accessdate=2008-05-26}}</ref>.
| |
| | |
| ==External links==
| |
| *[http://www.rxlist.com/cgi/generic/doxazo.htm Information about Cardura from rxlist.com]
| |
| *[http://www.bmj.com/cgi/content/full/326/7381/170/DC1 [[BMJ]] article about Cardura.]
| |
| *[http://www.pslgroup.com/dg/1fc576.htm Article about Cardura]
| |
| *[http://www.carduraxl.com/ Pfizer Site]
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| | |
| {{Antihypertensives and diuretics}}
| |
| {{Urologicals}}
| |
| {{SIB}}
| |
| [[Category:Alpha blockers]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |
| | |
| [[hr:Doksazosin]]
| |
| [[hu:Doxazozin]]
| |